Ligand Pharma – (NASDAQ:LGND)

Finance December 18, 2015

ROTH Capital Has Just Reaffirmed $146.0 Target Price Per Share on Ligand Pharma (NASDAQ:LGND) stock, While They’ve Also Reiterated Their Buy Rating

Ligand Pharma (NASDAQ:LGND) Rating Reaffirmed Professional analysts at ROTH Capital now has a $146.0 PT on Ligand Pharma (NASDAQ:LGND). ROTH Capital and their recent PT…

Finance December 18, 2015

New York: Ligand Pharma (NASDAQ:LGND) Stock Has Just Had Its Buy Rating Reiterated by ROTH Capital. Shares now Have a $146 Target

Ligand Pharma (NASDAQ:LGND) Rating Reaffirmed Recently, In a recent report issued to investors and clients on Friday, 18 December, Ligand Pharma (NASDAQ:LGND) shares have had…